For every patient recruited onto a commercial clinical trial between 2016/2017 and 2017/2018, the NHS in England received £9,189 from life sciences companies, and where a trial drug replaced the standard of care treatment, saved £5,813 (1).

To date, the Life Sciences Industrial Strategy, Sector Deals and R&D Roadmap have laid out commitments to enhancing the UK clinical research environment and have begun to address some of the existing challenges.

The response to the COVID-19 pandemic and the preparations being made for the end of the UK’s transition period with the European Union have created an even greater impetus for the transformational change needed as the UK looks to be a global leader in clinical research.

This report looks at how the UK clinical research environment has historically performed, highlighting areas for improvement. The pre-COVID-19 data here from 2018 articulates the UK’s performance across phases (I, II and III) and disease areas (Oncology, Nervous System, Cardio-metabolic, Immunology and Infectious diseases). Put in the context of the international landscape, this report highlights where the UK is competitive and where we fall behind other countries. This report also includes new data from Belgium and Hungary, which gives us additional granularity on performance across Europe.